COVID 19
Conditions
Brief summary
Descriptive prospective study to investigate the prevalence of COVID 19 during ambulant screening
Detailed description
The exact prevalence of COVID-19 is unknown. Due to the relatively high number of diagnosed, symptomatic infections despite a strict policy, we expect a high prevalence of COVID 19 throughout the entire population. The risk that an asymptomatic carrier who is admitted to the hospital for a (semi)urgent surgery, treatment of investigation transfers the virus to the hospital staff is very high, and vice versa. This risk is even higher during surgery, where intubation is necessary. Therefore we would like to pre-screen all patients ambulantly on the presence of COVID 19 since there is no consensus for screening at the moment. The golden standard is the SARS CoV-2 PCR on the nasopharyngeal sample together with a CT scan of the lungs. Patients in which a bloodsample is taken as standard of care procedure in this ambulant screening will be asked to give more blood for further investigation. On top of this standard of care screening, we will perform a questionnaire at the pre-operative visit which evaluates the possible occurence of certain symptoms in the last 2 weeks. These symptoms are fever, anorexia, cough, diarrhea, sneezing, vomiting, dyspnea, headache, rhinorrhea, loss of smell, muscle pain, sputum, sore throat and fatigue. Patients were also asked if one of their housemates are affected by these symptoms. Furthermore, 2 weeks after surgery, patient will be contacted to phone in order to fill the same questionnaire.
Interventions
OTHERQuestionnaire
Questionnaire
Sponsors
Jessa Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All adult patients \> 18 years scheduled for a (semi) urgent surgery, hematological or oncological treatment or elektrophysiciological investigations in the Jessa hospital
Exclusion criteria
* Patients \< 18 years * Adult patients who are unable the give informed consent * Language barrier
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of symptoms | at the ambulant screening | Prevalence of fever, cough, anorexia, fatigue, diarrhea, vomiting, dyspnee, sore throat and sputum |
| Prevalence of positive Sars CoV-2 PCR | at the ambulant screening | Prevalence of positive COVID 19 tests in patients planned for surgery, treatment or investigation in the hospital |
| Prevalence of positive radiological findings | at the ambulant screening | Prevalence of positive radiological findings in CT scans of the lungs of planned for surgery, treatment or investigation in the hospital |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of symptoms | 2 weeks after surgery or treatment | Prediction of symptoms of COVID 19, based on evaluated baseline questionnaire |
Countries
Belgium
Outcome results
None listed